Fifty 1 Labs and UAV Corp Complete Historic REVIVE Trial, Pioneering Long COVID Treatment

Fifty 1 Labs, Inc. (OTC: FITY), in collaboration with UAV Corp (OTC: UMAV), has announced the completion of the REVIVE Adaptive Platform Trial, a landmark Phase III study that stands as the largest Long COVID trial conducted to date. This randomized, double-blind trial, which involved over 600 participants and was conducted in partnership with leading institutions such as Stanford and Duke, showcased a significant treatment benefit through the use of repurposed medicines. The trial, powered by Fifty 1 Labs' proprietary AI platform, not only sets a new benchmark in the fields of drug repurposing and personalized medicine but also aligns with the company's strategic goals to dominate the $320.6 billion functional medicine market, explore strategic acquisitions, and progress towards uplisting to OTCQB and Nasdaq.

The success of the REVIVE trial underscores the potential of repurposed medicines in addressing Long COVID, a condition that has affected millions worldwide, highlighting the importance of innovative approaches in healthcare. This achievement not only represents a breakthrough in the treatment of Long COVID but also demonstrates Fifty 1 Labs' commitment to leveraging technology and science to improve health outcomes. For more details on the trial and its implications, visit https://ibn.fm/Vq9L8.